Autologous Stem Cell-Derived Dopaminergic Neurons for Parkinson's Disease (NCT06687837)

Overview

NCT06687837 is a Phase 1 clinical trial evaluating the safety and preliminary efficacy of autologous stem cell-derived dopaminergic neuron transplantation in patients with Parkinson's disease. This trial represents a cutting-edge cell replacement therapy approach that aims to restore dopaminergic signaling in the striatum through transplantation of patient-derived neurons["@stemcellpd2023"].

Overview

NCT06687837 is a Phase 1 clinical trial evaluating the safety and preliminary efficacy of autologous stem cell-derived dopaminergic neuron transplantation in patients with Parkinson's disease. This trial represents a cutting-edge cell replacement therapy approach that aims to restore dopaminergic signaling in the striatum through transplantation of patient-derived neurons["@stemcellpd2023"].

The trial uses induced pluripotent stem cell (iPSC) technology to generate dopaminergic neurons from the patient's own cells, minimizing the risk of immune rejection and eliminating ethical concerns associated with embryonic stem cells. These neurons are designed to integrate into the host brain and restore function to damaged dopaminergic pathways["@ipsc2024"].

<div class="infobox">
| Parameter | Value |
|-------------|----------|
| NCT Number | NCT06687837 |
| Phase | Phase 1 |
| Status | Recruiting |
| Sponsor | [To be confirmed from ClinicalTrials.gov] |
| Enrollment | [To be confirmed] |
| Study Type | Interventional |
| Condition | Parkinson's Disease |
</div>

Mechanism of Action

Cell Replacement Strategy

The fundamental approach of this trial is cell replacement therapy - transplanting dopaminergic neurons to replace those lost in Parkinson's disease. The mechanism involves several key steps[@dopaminergic2024]:

Expected Therapeutic Effects

The transplanted dopaminergic neurons are expected to:

• Restore Dopamine Production: Functional neurons synthesize and release dopamine
• Reinnervate Striatum: Axonal projections form connections with striatal medium spiny neurons
• Improve Motor Function: Recovery of normal motor control through restored dopaminergic signaling
• Reduce Levodopa Requirements: Potential for reduced medication needs over time

Trial Design

Inclusion Criteria

• Diagnosis of idiopathic Parkinson's disease
• Age [specific range to be confirmed]
• Disease duration [specific duration to be confirmed]
• Motor complications despite optimized medical therapy
• [Additional criteria from trial protocol]

Intervention

Autologous iPSC-derived Dopaminergic Neuron Transplantation:

• Cell source: Patient's own somatic cells reprogrammed to iPSCs
• Differentiation protocol: Directed differentiation toward midbrain dopaminergic lineage
• Delivery method: Stereotactic surgical implantation into bilateral putamen
• Dose: [Specific cell number to be confirmed]

Endpoints

Primary Endpoint:

• Safety and tolerability at 12 months post-transplantation
• Adverse events, serious adverse events
• Immunological responses to transplanted cells

• Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor)
• Change in Hoehn and Yahr stage
• Change in Levodopa-equivalent daily dose (LEDD)
• PET imaging of dopamine transporter binding
• Quality of life measures (PDQ-39)

Assessment Schedule

• Baseline: Pre-treatment evaluation
• Surgery: Day 0 (transplantation)
• Month 3: Early safety and preliminary efficacy
• Month 6: Comprehensive motor and functional assessment
• Month 12: Primary endpoint assessment
• Month 24: Long-term follow-up

Scientific Rationale

Parkinson's Disease Pathology

Parkinson's disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). These neurons project to the striatum (caudate and putamen) and form the nigrostriatal pathway that controls motor function. Loss of these neurons leads to:

• Motor symptoms: Tremor, bradykinesia, rigidity, postural instability
• Non-motor symptoms: Sleep disorders, depression, cognitive impairment
• Long-term complications: Motor fluctuations, dyskinesia

Rationale for Cell Therapy

Current treatments for PD are symptomatic and do not address the underlying neurodegeneration[@clinical2023]:

• Levodopa: Effective initially but causes long-term complications
• Deep Brain Stimulation: Invasive, requires hardware implantation
• Gene Therapy: Targets specific molecular pathways but doesn't replace lost neurons

• Replacing lost neurons with functional equivalents
• Potentially halting or reversing disease progression
• Providing continuous dopamine delivery physiologically

Autologous iPSC Advantages

The use of autologous (patient-derived) iPSCs provides several advantages:

• Immunocompatibility: Patient's immune system recognizes cells as "self"
• No Ethical Concerns: Avoids controversy around embryonic stem cells
• Personalized Medicine: Tailored to each patient's genetic background
• Reduced Immunosuppression: No need for long-term immunosuppressive drugs

Safety Considerations

Cell therapy approaches require careful safety monitoring[@safety2024]:

Tumorigenicity Risk

• iPSCs have potential for tumor formation if undifferentiated cells remain
• Rigorous purification protocols minimize this risk
• Long-term monitoring for abnormal growths

Immunological Considerations

• Autologous cells minimize immune rejection
• Monitoring for inflammatory responses
• Potential for graft-versus-host reaction (minimal with autologous cells)

Surgical Risks

• Intracranial hemorrhage
• Infection
• Adverse reactions to anesthesia
• Misplacement of cells

Dyskinesia Risk

• Over-dopaminization could cause dyskinesia
• Careful dose titration and monitoring
• Immunosuppression may be required in some cases

Current Status and Future Directions

This Phase 1 trial represents early-stage clinical development of cell therapy for Parkinson's disease. The field has evolved from early fetal tissue transplants to modern iPSC-based approaches:

Historical Context:

• Fetal ventral mesencephalic transplants (1980s-2000s): Showed proof of concept but limited by availability and ethical issues
• Embryonic stem cell-derived dopaminergic neurons: Clinical trials in progress
• iPSC-derived dopaminergic neurons: This trial represents cutting-edge approach

• Phase 2/3 trials to establish efficacy
• Optimization of cell doses and delivery methods
• Combination approaches with neuroprotective factors
• Use of allogeneic "off-the-shelf" iPSC lines

Competitive Landscape

Cell therapy for Parkinson's disease is an active area of development:

| Approach | Company/Institution | Stage | Key Features |
|----------|-------------------|-------|--------------|
| iPSC-derived DA neurons (NCT06687837) | Various | Phase 1 | Autologous, patient-specific |
| ES cell-derived DA neurons | BlueRock Therapeutics | Phase 1 | Allogeneic, bemdaneprocel |
| iPSC-derived DA neurons | Kyoto University | Phase 1/2 | Autologous (Japan) |
| AAV-based gene therapy | Various | Phase 2/3 | AADC gene delivery |

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Cell Therapy for Neurodegeneration](/mechanisms/cell-therapy-neurodegeneration)
• [Dopamine Replacement Therapies](/therapeutics/dopamine-replacement-therapies)
• [Stem Cell Research in Neurodegeneration](/mechanisms/stem-cell-research-neurodegeneration)
• [Clinical Trials Overview](/clinical-trials/overview)

External Links

• [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT06687837)
• [PubMed Search: Stem cell therapy Parkinson's](https://pubmed.ncbi.nlm.nih.gov/?term=stem+cell+therapy+parkinson+disease)
• [iPSC Research Resources](https://www.ipscell.com/)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Autologous Stem Cell-Derived Dopaminergic Neurons for Parkinson's Disease (NCT06687837) discovered through SciDEX knowledge graph analysis: